(Q36742845)

English

Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial

scientific article published in April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

Jens-Erik Beck Jensen

object named as

Jens-Erik Beck Jensen

5

0 references

Nigel Gilchrist

6

object named as

Nigel Gilchrist

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Jacques P Brown

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Christian Roux

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Ove Törring

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Pei-Ran Ho

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Christopher Recknor

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Matt Austin

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Andrea Wang

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Andreas Grauer

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Rachel B Wagman

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

publication date

1 April 2013

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

28

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

746-752

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

29 September 2017

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

29 September 2017

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

29 September 2017

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

29 September 2017

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

29 September 2017

Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

28 June 2018

Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

28 June 2018

Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Fracture risk remains reduced one year after discontinuation of risedronate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Changes in bone density and turnover after alendronate or estrogen withdrawal.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

The effect of postmenopausal estrogen therapy on bone density in elderly women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3617467

5 September 2018

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1808

21 January 2018

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23109251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The waning effect of postmenopausal estrogen therapy on osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23109251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23109251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23109251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/JBMR.1808

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36742845&oldid=1631474538"